PURPOSE: The purpose of this study was to compare functional interference and pain response outcomes using the Brief Pain Inventory (BPI) for patients treated with palliative radiotherapy to spine versus non-spine bones and determine if dose fractionation was associated with each group's respective response. MATERIALS AND METHODS: Patients treated for painful bone metastases with palliative radiotherapy during May 2003 to June 2007 were analyzed. The BPI was utilized at baseline and monthly for 6 months post-radiation. Pain response was determined using International Bone Metastases Consensus response definitions. Wilcoxon rank-sum test (for continuous variable), Fisher exact test (for categorical value), and two-way analysis of variance were used for comparisons, and a p value of ≤ 0.05 was considered statistically significant. RESULTS: Three hundred eighty-six patients were analyzed, 62% were treated with a single fraction, 38% with multiple fractions. Pain and functional interference scores significantly improved over time in both spine and non-spine sites. At 3 months, 42% of all patients had a partial response, and 25% had a complete response. Location of bone metastases and radiotherapy dose were not predictive factors for pain response nor functional interference following radiation treatment. CONCLUSION: Spine and non-spine bone metastases exhibited similar pain and functional interference improvements over a period of 6 months post-radiotherapy. There were, however, high attrition rates as expected with palliative studies, with approximately half the patients remaining in this study by 3 months and a fifth by 6 months. A single 8 Gy resulted in equal benefits in terms of both pain response and improvement in function.
PURPOSE: The purpose of this study was to compare functional interference and pain response outcomes using the Brief Pain Inventory (BPI) for patients treated with palliative radiotherapy to spine versus non-spine bones and determine if dose fractionation was associated with each group's respective response. MATERIALS AND METHODS:Patients treated for painful bone metastases with palliative radiotherapy during May 2003 to June 2007 were analyzed. The BPI was utilized at baseline and monthly for 6 months post-radiation. Pain response was determined using International Bone Metastases Consensus response definitions. Wilcoxon rank-sum test (for continuous variable), Fisher exact test (for categorical value), and two-way analysis of variance were used for comparisons, and a p value of ≤ 0.05 was considered statistically significant. RESULTS: Three hundred eighty-six patients were analyzed, 62% were treated with a single fraction, 38% with multiple fractions. Pain and functional interference scores significantly improved over time in both spine and non-spine sites. At 3 months, 42% of all patients had a partial response, and 25% had a complete response. Location of bone metastases and radiotherapy dose were not predictive factors for pain response nor functional interference following radiation treatment. CONCLUSION: Spine and non-spine bone metastases exhibited similar pain and functional interference improvements over a period of 6 months post-radiotherapy. There were, however, high attrition rates as expected with palliative studies, with approximately half the patients remaining in this study by 3 months and a fifth by 6 months. A single 8 Gy resulted in equal benefits in terms of both pain response and improvement in function.
Authors: William F Hartsell; Charles B Scott; Deborah Watkins Bruner; Charles W Scarantino; Robert A Ivker; Mack Roach; John H Suh; William F Demas; Benjamin Movsas; Ivy A Petersen; Andre A Konski; Charles S Cleeland; Nora A Janjan; Michelle DeSilvio Journal: J Natl Cancer Inst Date: 2005-06-01 Impact factor: 13.506
Authors: Pål Klepstad; Jon Håvard Loge; Petter C Borchgrevink; Tito R Mendoza; Charles S Cleeland; Stein Kaasa Journal: J Pain Symptom Manage Date: 2002-11 Impact factor: 3.612
Authors: Andre Konski; Jennifer James; William Hartsell; Mark H Leibenhaut; Nora Janjan; Walter Curran; Mack Roach; Deborah Watkins-Bruner Journal: Am J Clin Oncol Date: 2009-08 Impact factor: 2.339
Authors: E Gallizia; G Apicella; T Cena; M Di Genesio Pagliuca; L Deantonio; M Krengli Journal: Clin Transl Oncol Date: 2017-06-16 Impact factor: 3.405
Authors: Joanne M van der Velden; Anne L Versteeg; Helena M Verkooijen; Charles G Fisher; Edward Chow; F Cumhur Oner; Marco van Vulpen; Lorna Weir; Jorrit-Jan Verlaan Journal: Oncologist Date: 2017-05-03
Authors: Ori Barzilai; Anne L Versteeg; Arjun Sahgal; Laurence D Rhines; Mark H Bilsky; Daniel M Sciubba; James M Schuster; Michael H Weber; Peter Pal Varga; Stefano Boriani; Chetan Bettegowda; Michael G Fehlings; Yoshiya Yamada; Michelle J Clarke; Paul M Arnold; Ziya L Gokaslan; Charles G Fisher; Ilya Laufer Journal: Cancer Date: 2018-11-29 Impact factor: 6.860
Authors: Harald Rief; Thomas Welzel; Georg Omlor; Michael Akbar; Thomas Bruckner; Stefan Rieken; Matthias F Haefner; Ingmar Schlampp; Alexandros Gioules; Jürgen Debus Journal: BMC Cancer Date: 2014-07-05 Impact factor: 4.430
Authors: Ori Barzilai; Mary-Kate Amato; Lily McLaughlin; Anne S Reiner; Shahiba Q Ogilvie; Eric Lis; Yoshiya Yamada; Mark H Bilsky; Ilya Laufer Journal: Neurooncol Pract Date: 2017-07-22